Definitive Contract 75A50120C00162
Award Date
8/18/20
Potential Completion Date
2/28/22
Potential Value
$433K
Awardee
University Of Connecticut
Ultimate Awardee
Secretary Of State Connecticut
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Storrs, CT 06269, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
500
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The University of Connecticut (UConn) has been awarded a $1,103,886 firm-fixed-price definitive federal contract by the Food and Drug Administration (FDA) for research and development related to the impact of active pharmaceutical ingredients on in situ forming implants and understanding in vitro and in vivo performance differences. This contract, which has a completion date of September 29, 2026, was issued under the FDA's Broad Agency Announcement for research and development to support...
This is a $973,150.35 definitive, firm fixed price contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) for a study on the "Impact of Polymer Attributes on the Performance of In Situ Forming Implants." The contract has a completion date of September 9, 2023 and was awarded on March 6, 2020. UConn, a non-profit educational institution, will leverage its expertise in scientific research and specialized services to support this FDA study....
This firm fixed price purchase order contract, valued at $22,610.38, was awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh to the University of Connecticut (UConn) to develop resources for designing age-friendly workplaces in manufacturing support. UConn, a non-profit 1862 land-grant educational institution, will leverage its multidisciplinary expertise to support this federal priority. The contract has no set-aside designation. UConn has a broad portfolio of federal...
The University of Connecticut has been awarded a definitive contract by the Department of Health and Human Services Food and Drug Administration to continue processing liposomal nanoparticles as reference materials for drug product development. With a potential value of $349,364, this time and materials contract does not have a set-aside designation and is to be completed by May 31, 2023. As the prime contractor, the University will utilize its expertise in nanotechnology and materials...
This is a $219,991 cost-no-fee definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct research on the "Continuous Manufacturing of Liposomes: Materials Understanding and Process Control." The contract is part of the FDA's broader program on continuous manufacturing of liposomes, a type of drug delivery system. UConn, a leading public research institution, will leverage its expertise in materials science, engineering,...
This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Connecticut for "Assessing Long-Acting Injectable Formulations Using In Vivo Imaging". The potential value of the contract is $1,131,742.00 and it has a completion date of September 29, 2024. The contract is not set aside for a specific business category. Under this contract, the University of Connecticut is conducting research and analysis on...
The National Institute of Child Health and Human Development (NICHD) awarded a firm-fixed-price purchase order contract to the University of Connecticut Health Center (UCHC) for gene editing services. The contract, valued at $3,882.00, has a completion date of February 28, 2021. UCHC is a state-controlled institution of higher learning that has an extensive portfolio of federal contracts and grants, including work with the Department of Defense and Defense Health Agency on medical training and...
This is a firm fixed price purchase order awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to the University of Connecticut Health Center (UCHC). The $100,028 award does not use a set-aside and has an estimated completion date of August 15, 2024. As a state entity and educational institution, UCHC provides a variety of services to federal agencies, including medical research, healthcare, and education. The award is likely for services related to...
The U.S. Food and Drug Administration (FDA) awarded a $1,530,889.00 definitive, cost-no-fee contract to the University of Connecticut (UConn) to conduct research on "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". This is a 4-year contract running from September 2023 to September 2027. UConn, a non-profit research university, will be the prime contractor with no set-aside designation....
This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Vaxxas PTY LTD, a for-profit company based in Australia, for the development of a Micro Array Patch (MAP) to deliver a vaccine against the H5N1 pandemic strain of influenza. The total ceiling value of the contract is $28,521,971.80 with a period of performance through December 30, 2026. No set-aside designation was used for this award. The University of Queensland, also...